Skip to content

Dexamethasone Versus Ondansetron for Preventing Post-Spinal Hypotension in Preeclampsia

Intravenous Dexamethasone Versus Ondansetron in the Prevention of Post-Spinal Hypotension in Preeclampsia Patients Undergoing Caesarean Delivery: A Prospective Randomized Clinical Trial

Status
Not yet recruiting
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07793760
Enrollment
110
Registered
2026-08-31
Start date
2026-10-01
Completion date
2027-11-01
Last updated
2026-08-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cesarean Section, Preeclampsia, Spinal Anesthesia-Induced Hypotension

Keywords

Dexamethasone, Ondansetron, Post-Spinal Hypotension, Preeclampsia, Spinal Anesthesia, Cesarean Delivery, Optic Nerve Sheath Diameter, Vasopressors

Brief summary

This study compares the efficacy and safety of intravenous dexamethasone versus intravenous ondansetron in preventing low blood pressure (hypotension) following spinal anesthesia in pregnant women with preeclampsia undergoing scheduled cesarean delivery. Spinal anesthesia is the preferred anesthetic method for cesarean delivery, but it frequently causes a sudden drop in maternal blood pressure. In patients with preeclampsia, post-spinal hypotension can compromise blood flow to the placenta and vital organs. While traditional vasopressor medications are used to restore blood pressure, non-adrenergic prophylactic agents such as dexamethasone and ondansetron may help maintain hemodynamic stability through different physiological pathways. Participants will be randomly assigned to receive either intravenous dexamethasone (8 mg) or intravenous ondansetron (4 mg) 15 minutes prior to the initiation of spinal anesthesia. Blood pressure, heart rate, vasopressor requirements, optic nerve sheath diameter, and maternal and neonatal outcomes will be monitored throughout the surgery and during the immediate postoperative period.

Interventions

DRUGDexamethasone

Intravenous dexamethasone 8 mg diluted with 0.9% normal saline to a total volume of 10 mL, administered slowly over approximately one minute, 15 minutes before the induction of spinal anesthesia.

DRUGOndansetron

Intravenous ondansetron 4 mg diluted with 0.9% normal saline to a total volume of 10 mL, administered slowly over approximately one minute, 15 minutes before the induction of spinal anesthesia.

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 40 Years
Healthy volunteers
No

Inclusion criteria

* Pregnant women aged 18 to 40 years. * American Society of Anesthesiologists (ASA) physical status III. * Diagnosed with preeclampsia (new onset of hypertension ≥140/90 mmHg with proteinuria occurring after 20 weeks of gestation according to ACOG and ISSHP guidelines). * Scheduled for elective cesarean delivery under spinal anesthesia.

Exclusion criteria

* Peripartum bleeding. * Obesity (body mass index ≥40 kg/m²). * Coagulation disorders (platelet count \< 75,000/μL). * Neurological disorders. * Previous or current systemic corticosteroid therapy. * Known cardiac disease. * History of diabetes mellitus. * Renal dysfunction (serum creatinine \> 2 mg/dL). * Hepatic dysfunction (serum liver enzymes \> 2 times the upper limit of normal). * Known hypersensitivity to dexamethasone, ondansetron, or any component of the study medications. * Emergency cesarean delivery. * Known fetal congenital anomalies.

Design outcomes

Primary

MeasureTime frameDescription
Incidence of post-spinal hypotension1 hourNumber of participants with a decrease in systolic blood pressure below 80% of baseline.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 1, 2026